Jump to content

Lesogaberan

From Wikipedia, the free encyclopedia
Lesogaberan
Names
Preferred IUPAC name
[(2R)-3-Amino-2-fluoropropyl]phosphinic acid
Other names
AZD-3355
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
ECHA InfoCard 100.133.162Edit this at Wikidata
UNII
  • InChI=1S/C3H9FNO2P/c4-3(1-5)2-8(6)7/h3,8H,1-2,5H2,(H,6,7)/t3-/m1/s1☒N
    Key: LJNUIEQATDYXJH-GSVOUGTGSA-N☒N
  • InChI=1/C3H9FNO2P/c4-3(1-5)2-8(6)7/h3,8H,1-2,5H2,(H,6,7)/t3-/m1/s1
    Key: LJNUIEQATDYXJH-GSVOUGTGBQ
  • O=[PH](O)C[C@H](F)CN
Properties
C3H9FNO2P
Molar mass 141.082g·mol−1
Except where otherwise noted, data are given for materials in theirstandard state(at 25 °C [77 °F], 100 kPa).

Lesogaberan(AZD-3355) was[1]an experimental drug candidate developed byAstraZenecafor the treatment ofgastroesophageal reflux disease(GERD).[2]As aGABABreceptoragonist,[3]it has the samemechanism of actionasbaclofen,but is anticipated to have fewer of thecentral nervous systemside effects that limit the clinical use of baclofen for the treatment of GERD.[4]

References

[edit]
  1. ^AstraZeneca."AZD3355".Retrieved30 December2011.
  2. ^Bredenoord, Albert J. (2009). "Lesogaberan, a GABABagonist for the potential treatment of gastroesophageal reflux disease ".IDrugs.12(9): 576–584.PMID19697277.
  3. ^Alstermark; Amin, K; Dinn, SR; et al. (2008). "Synthesis and Pharmacological Evaluation of Novel γ-Aminobutyric Acid Type B (GABAB) Receptor Agonists as Gastroesophageal Reflux Inhibitors".Journal of Medicinal Chemistry.51(14): 4315–4320.doi:10.1021/jm701425k.PMID18578471.
  4. ^Brian E. Lacy; Robert Chehade; Michael D. Crowell (2010). "Lesogaberan".Drugs of the Future.35(12): 987–992.doi:10.1358/dof.2010.035.012.1540661.S2CID258021903.